ANI director granted 4,357 restricted shares

TANNENBAUM RENEE P reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

TANNENBAUM RENEE P reported acquisition or exercise transactions in this Form 4 filing.

ANI Pharmaceuticals director Renee P. Tannenbaum received a grant of 4,357 shares of common stock as a restricted stock award on May 21, 2026. The award carries no purchase price and will vest in full on May 21, 2027, if conditions are met.

Following this compensation-related grant, Tannenbaum directly holds 29,514 shares of ANI Pharmaceuticals common stock. This is a routine equity award to a board member rather than an open-market transaction.

Insider Trade Summary

Grant/Award: 4,357 shares

Grant/Award 1 txn

Insider TANNENBAUM RENEE P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,357	$0.00	$0.00

Holdings After Transaction: Common Stock — 29,514 shares (Direct)

Footnotes (1)

1. F1. Represents a restricted stock award that will vest in full on May 21, 2027.

Key Figures

Restricted stock award size: 4,357 shares Grant price: $0.0000 per share Shares after transaction: 29,514 shares +1 more

4 metrics

Restricted stock award size 4,357 shares Grant to director on May 21, 2026

Grant price $0.0000 per share Equity compensation, no cash paid

Shares after transaction 29,514 shares Director’s direct holdings following grant

Vesting date May 21, 2027 Restricted stock award vests in full on this date

Key Terms

restricted stock award, grant, award, or other acquisition, Form 4, non-derivative

4 terms

restricted stock award financial

"Represents a restricted stock award that will vest in full on May 21, 2027."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"transaction_type: non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Renee P. Tannenbaum?

ANI Pharmaceuticals reported that director Renee P. Tannenbaum received a grant of 4,357 shares of common stock as a restricted stock award. This was classified as a grant or award acquisition, not an open-market purchase or sale.

When do Renee P. Tannenbaum’s new ANI Pharmaceuticals (ANIP) restricted shares vest?

The 4,357-share restricted stock award to director Renee P. Tannenbaum will vest in full on May 21, 2027. Vesting means the shares become fully owned by her if the applicable service or other conditions are satisfied by that date.

How many ANI Pharmaceuticals (ANIP) shares does Renee P. Tannenbaum hold after this Form 4?

After receiving the 4,357-share restricted stock award, Renee P. Tannenbaum directly holds 29,514 shares of ANI Pharmaceuticals common stock. This figure reflects her direct ownership position immediately following the reported compensation-related transaction.

Was cash paid for Renee P. Tannenbaum’s ANI Pharmaceuticals (ANIP) stock grant?

No cash was paid for this grant; the reported transaction price per share was 0.0000. The 4,357 shares were awarded as equity compensation to Renee P. Tannenbaum rather than purchased in an open-market transaction.

Is the ANI Pharmaceuticals (ANIP) Form 4 a buy or sell by Renee P. Tannenbaum?

The Form 4 reflects an acquisition through a grant, not a market buy or sell. It is coded as a grant, award, or other acquisition, meaning shares were issued to Renee P. Tannenbaum as compensation rather than traded on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 09:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TANNENBAUM RENEE P

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A(1)		4,357	A	$0	29,514	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in full on May 21, 2027.

Remarks:

	/s/ Renee P. Tannenbaum, by attorney-in-fact Meredith W. Cook	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)